or Try an Advanced Search...

    Technical Analysis for IOBT - IO Biotech, Inc.

    Grade Last Price % Change Price Change
    F 0.79 -4.34% -0.04
    IOBT closed down 5.68 percent on Wednesday, November 20, 2024, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical IOBT trend table...
    Date Alert Name Type % Chg
    New Downtrend Bearish -4.34%
    Wide Bands Range Expansion -4.34%
    Oversold Stochastic Weakness -4.34%
    Stochastic Buy Signal Bullish -9.77%
    Lower Bollinger Band Walk Weakness -9.77%
    Inside Day Range Contraction -9.77%
    Wide Bands Range Expansion -9.77%
    Oversold Stochastic Weakness -9.77%
    Lower Bollinger Band Walk Weakness -10.23%
    Wide Bands Range Expansion -10.23%
    Older End-of-Day Signals for IOBT ...

       Recent Intraday Alerts

    Alert Time
    Lower Bollinger Band Support 4 minutes ago
    New 52 Week Low 42 minutes ago
    Down 10% 42 minutes ago
    3x Volume Pace about 1 hour ago
    2x Volume Pace about 1 hour ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    IOBT Chart by TradingView
    Basic chart:

    Profile

    IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Immune System Treatment Of Cancer Cancer Therapies Anti Cancer Therapies Urea Cycle

    Is IOBT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 IO Biotech GAAP EPS of -$0.36 misses by $0.09
    Nov 12 IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
    Nov 7 IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
    Nov 3 Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation
    Oct 4 IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
    Sep 18 Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket
    Sep 16 Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
    Sep 14 IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
    Sep 2 IO Biotech’s melanoma treatment trial to continue after IDMC review
    Aug 30 IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
    See more IOBT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.098
    52 Week Low 0.7327
    Average Volume 485,831
    200-Day Moving Average 1.35
    50-Day Moving Average 1.09
    20-Day Moving Average 1.09
    10-Day Moving Average 0.96
    Average True Range 0.12
    RSI (14) 32.89
    ADX 25.01
    +DI 14.29
    -DI 27.63
    Chandelier Exit (Long, 3 ATRs) 1.00
    Chandelier Exit (Short, 3 ATRs) 1.15
    Upper Bollinger Bands 1.43
    Lower Bollinger Band 0.76
    Percent B (%b) 0.1
    BandWidth 61.40
    MACD Line -0.09
    MACD Signal Line -0.05
    MACD Histogram -0.0366
    Fundamentals Value
    Market Cap 54.06 Million
    Num Shares 65.9 Million
    EPS -2.36
    Price-to-Earnings (P/E) Ratio -0.35
    Price-to-Sales 0.00
    Price-to-Book 0.77
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.99
    Resistance 3 (R3) 1.00 0.95 0.96
    Resistance 2 (R2) 0.95 0.91 0.95 0.95
    Resistance 1 (R1) 0.89 0.89 0.87 0.88 0.94
    Pivot Point 0.84 0.84 0.83 0.84 0.84
    Support 1 (S1) 0.78 0.80 0.76 0.77 0.70
    Support 2 (S2) 0.73 0.78 0.73 0.69
    Support 3 (S3) 0.67 0.73 0.68
    Support 4 (S4) 0.66